Eesti - eesti - Ravimiamet

medochemie limited - valsartaan - õhukese polümeerikattega tablett - 160mg 280tk; 160mg 56tk; 160mg 90tk; 160mg 60tk; 160mg 30tk; 160mg 7tk

Eesti - eesti - Ravimiamet

medochemie limited - memantiin - õhukese polümeerikattega tablett - 5mg 112tk; 5mg 70tk; 5mg 100tk; 5mg 14tk; 5mg 56tk; 5mg 60tk; 5mg 50tk; 5mg 28tk

Eesti - eesti - Ravimiamet

medochemie limited - rosuvastatiin - õhukese polümeerikattega tablett - 10mg 100tk; 10mg 28tk; 10mg 84tk; 10mg 56tk; 10mg 90tk; 10mg 20tk

Eesti - eesti - Ravimiamet

medochemie limited - valsartaan - õhukese polümeerikattega tablett - 80mg 28tk; 80mg 14tk; 80mg 60tk; 80mg 7tk; 80mg 280tk; 80mg 30tk; 80mg 98tk; 80mg 90tk

Eesti - eesti - Ravimiamet

medochemie limited - memantiin - õhukese polümeerikattega tablett - 20mg 56tk; 20mg 1000tk; 20mg 30tk; 20mg 112tk; 20mg 14tk; 20mg 50tk; 20mg 70tk

Eesti - eesti - Ravimiamet

medochemie limited - memantiin - õhukese polümeerikattega tablett - 10mg 56tk; 10mg 28tk; 10mg 1000tk; 10mg 30tk; 10mg 100tk; 10mg 70tk; 10mg 14tk; 10mg 60tk

Eesti - eesti - Ravimiamet

medochemie limited - rosuvastatiin - õhukese polümeerikattega tablett - 20mg 100tk; 20mg 30tk; 20mg 20tk; 20mg 28tk; 20mg 84tk; 20mg 60tk; 20mg 14tk; 20mg 90tk

Eesti - eesti - Ravimiamet

medochemie limited - tsinnarisiin+dimenhüdrinaat - tablett - 20mg+40mg 50tk; 20mg+40mg 100tk; 20mg+40mg 20tk

Eesti - eesti - Ravimiamet

medochemie limited - memantiin - õhukese polümeerikattega tablett - 15mg 112tk; 15mg 28tk; 15mg 100tk; 15mg 30tk; 15mg 1000tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroksabaan - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - antitrombootilised ained - täiskasvanud patsientidel, kellele tehti plaaniline puusa- või põlveliigese asendamise operatsiooni venoosse trombemboolia (vte) ennetamine. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 haemodynamically ebastabiilne pe patsientidel). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 ja 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. ravi süvaveenide tromboos (dvt) ja kopsuarteri emboolia (pe), ning ennetamine korduvate digi-tv ja pe täiskasvanutel. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.